Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Holding ROIV?
Track your performance easily
ROIV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.47 - $13.06
Previous Close$11.66
Volume4.19M
Average Volume (3M)5.88M
Market Cap
$8.53B
Enterprise Value$3.69B
Total Cash (Recent Filing)$5.68B
Total Debt (Recent Filing)$379.06M
Price to Earnings (P/E)2.1
Beta0.61
Next Earnings
Nov 12, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.57
Shares Outstanding739,521,824
10 Day Avg. Volume3,293,579
30 Day Avg. Volume5,878,245
Standard Deviation0.20
R-Squared0.14
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)54.47
Price to Cash Flow (P/CF)-11.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.29
Enterprise Value/Gross Profit33.75
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$16.17Price Target Upside37.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Roivant Sciences News
PremiumCompany Announcements
Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
PremiumCompany Announcements
Roivant Sciences Subsidiary Acquired for $1.2 BillionBulls Say, Bears Say
Bulls Say
Dermavant SaleROIV's sale of Dermavant to Organon is set to bring in up to $1.2 billion in payments, including upfront, milestone payments, and royalties, providing substantial financial upside.
Executive CompensationThe executive incentive compensation structure at ROIV is fully aligned with shareholders, offering significant rewards for long-term stock-price appreciation and durable value creation.
Research And Development PipelineROIV is advancing its research and development pipeline with the imminent opening of enrollment for the Ph2 PHocus study of mosliciguat, a promising treatment for pulmonary hypertension associated with interstitial lung disease.
Bears Say
Market CompetitionZoryve’s growth in psoriasis segment (+8% Q/Q) outpaced VTAMA (+3% Q/Q) this quarter.
Product PerformanceVTAMA sales were 15% below consensus.
Sales ForecastVTAMA's launch in psoriasis has slowed, and analysts are taking a more conservative stance given what has been seen in psoriasis.
---
Ownership Overview
25.76% Insiders
7.61% Mutual Funds
0.74% Other Institutional Investors
53.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.46 and its highest was $13.05 in the past 12 months.
What is Roivant Sciences’s market cap?
Currently, no data Available
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Nov 12, 2024 which is in 3 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Aug 08, 2024. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.363.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -$0.23.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 739,521,850 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of $0.12 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went up 6.686%.
Which hedge fund is a major shareholder of Roivant Sciences?
Among the largest hedge funds holding Roivant Sciences’s share is Viking Global Investors LP. It holds Roivant Sciences’s shares valued at 731M.
---
Roivant Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.17 (37.62% Upside)
$16.17 (37.62% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 8.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.17%
12-Months-Change
Fundamentals
Return on Equity
149.26%
Trailing 12-Months
Asset Growth
204.05%
Trailing 12-Months
Company Description
Roivant Sciences
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q1 2024
0:00 / 0:00
---
ROIV Stock 12 Month Forecast
Average Price Target
$16.17
▲(37.62% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Fate Therapeutics
―
Recursion Pharmaceuticals
―
Denali Therapeutics
―
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+72.17%
reiterated a buy rating 5 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.17% per trade.
---